Traders should anticipate continued share price pressure due to the significant dilution from this offering. Monitor the company's cash runway and progress toward FDA approval for INO-3107, as these will be key factors in determining whether the capital raise provides sufficient runway to achieve value inflection points or merely delays potential insolvency.
Price Chart
Executive Summary
Inovio Pharmaceuticals entered into a material definitive agreement (Item 1.01) to conduct a public offering of 12.5 million shares of common stock and accompanying warrants, raising approximately $16.45 million in gross proceeds before expenses. This offering, combined with a recent capital raise, indicates the company is securing funds amid ongoing uncertainty about its ability to continue as a going concern, leading to significant shareholder dilution.
Key Financial Metrics
Key Facts
- Inovio Pharmaceuticals is conducting a public offering of 12,500,000 shares of common stock, Series A warrants to purchase up to 12,500,000 shares, and Series B warrants to purchase up to 12,500,000 shares.
- The combined public offering price is $1.40 per share and accompanying warrants, with gross proceeds of $17.5 million and net proceeds of approximately $16.45 million after underwriting discounts.
- The offering includes an over-allotment option for up to an additional 1,875,000 shares and warrants.
- This capital raise follows a recent 424B5 filing, indicating a pattern of dilutive financing to fund operations.
- The company has acknowledged substantial doubt about its ability to continue as a going concern.
Financial Impact
Raises $16.45 million in net proceeds through issuance of 12.5 million common shares and 25 million warrants, causing immediate and significant shareholder dilution.
Risk Factors
- Substantial shareholder dilution from the issuance of new shares and warrants
- Ongoing uncertainty about the company's ability to continue as a going concern
- Risk that the raised capital will not be sufficient to achieve commercial milestones or secure additional funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-142885 |
| Document: d137120dex42.htm | 0001193125-26-142885 |
| Document: d137120dex43.htm | 0001193125-26-142885 |
| Document: d137120dex41.htm | 0001193125-26-142885 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 31, 2026 9w ago | 8-K | $0.6770 $1.29 | ▼ −90.55% | ▼ −87.56% | $1.20 (−76.51%) |
Jul 30, 2026 9w ago | 424B5 | $0.6770 $1.29 | ▼ −90.55% | ▼ −87.56% | $1.20 (−76.51%) |
Jul 30, 2026 9w ago | Press Release | $0.6560 $1.26 | ▼ −92.07% | ▼ −88.11% | $1.20 (−82.16%) |
Jul 13, 2026 11w ago | EFFECT | $1.16 $0.7364 | ▲ +36.52% | ▲ +39.70% | $1.20 (−3.02%) |
Jul 2, 2026 13w ago | S-3 | $1.22 $0.6560 | ▲ +46.23% | ▲ +45.81% | $1.20 (+2.05%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.10 $1.19 | ▲ +8.18% | ▲ +6.29% | $1.20 (+8.64%) |
Apr 6, 2026 25w ago | 8-K | $1.13 $1.14 | ▼ −0.89% | ▲ +8.10% | $1.20 (−5.75%) |
Apr 2, 2026 26w ago | 424B5 | $1.13 $1.12 | ▲ +0.89% | ▲ +10.76% | $1.20 (−5.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access